chartexchange

IBRX270115P00004000
IBRX Jan 15 2027 4.00 Put
optionOPRA

EODOct 15, 2026
0.20USD0.000%(0.00)80Vol272OI
Loading…
Underlying
Underlying Price
$8.48
Type
Put
Strike
4
Expiration
Jan 15, 2027
DTE
87d
Moneyness
OTM
Intrinsic
$0.00
IBRX 4 Put Across Expirations
ExpirationDTELastChangeVolOpen Int
Oct 23, 20263d——00
Oct 30, 202610d$0.02+0.00%10
Nov 6, 202617d——00
Nov 13, 202624d——00
Nov 20, 202631d$0.03-40.00%16
Nov 27, 202638d——00
Dec 18, 202659d——00
Jan 15, 202787d$0.20+0.00%80272
Mar 19, 2027150d$0.33-48.44%114
Apr 16, 2027178d——00
May 21, 2027213d——00
Aug 20, 2027304d——00
Nov 19, 2027395d$0.90+0.00%82
Jan 21, 2028458d$1.32-37.14%121
Mar 17, 2028514d$0.50-54.55%4041
Jan 19, 2029822d——00
IBRX Nearby Strikes · Jan 15, 2027
StrikeLastChangeVolOpen IntMoneyness
1 P$0.05+66.67%2215OTM
1.5 P$0.19+90.00%6299OTM
2 P$0.03-40.00%722,010OTM
2.5 P$0.05+0.00%18,454OTM
3 P$0.05-50.00%182,647OTM
3.5 P$0.12+20.00%21,305OTM
4 P$0.20+0.00%80272OTM
4.5 P$0.20+25.00%20439OTM
5 P$0.29+3.57%1724,922OTM
5.5 P$0.30-14.29%3033,349OTM
7.5 P$0.90+20.00%12122,697OTM
9 P$1.62+5.88%7252,470ITM
10 P$2.06+1.48%506,506ITM
IBRX Profile

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.